Results 1 to 10 of about 13,844 (146)

Loss of ELF2 drives topotecan resistance in retinoblastoma revealed by genome-wide CRISPR-Cas9 screening [PDF]

Cell Death and Disease
The topoisomerase I inhibitor topotecan is an effective chemotherapeutic agent for retinoblastoma; however, treatment resistance remains a major clinical challenge, and its mechanisms remain elusive.
Jingyi Jiang, Zihua Jiang, Qian Luo, Xi Chen, Jiejie Zhuang, Jiaxin Chen, Qingqing Mu, Jin Qiu, Yan Li, Shuxia Chen, Ping Zhang, Keming Yu, Shuilian Chen, Guei-Sheung Liu, Jing Zhuang   +14 more
doaj   +2 more sources

High-dose topotecan (90 and 180 μG) for recurrent subretinal and vitreous seeding in retinoblastoma [PDF]

American Journal of Ophthalmology Case Reports
Purpose: To report on the use of intravitreal high-dose topotecan (90 and 180 μG) for recurrent subretinal and vitreous retinoblastoma, the toxicity of these injections, and the use of a 180-μG injection of intravitreal topotecan in humans. Observations:
David H. Abramson, Jasmine H. Francis
doaj   +2 more sources

In Vitro Stability and Preclinical Safety Evaluation of High-Dose Intravitreal Topotecan in Rabbits: Impact of Dose and Concentration [PDF]

Ophthalmology Science
Purpose: To assess the stability of concentrated solutions of topotecan and the ocular and systemic safety of administering repeated very high doses of intravitreal (IVi) topotecan in rabbits. Design: Experimental study.
María J. Del Sole, PhD, Pablo Nejamkin, PhD, Javier Opezzo, PhD, Debora Chan, PhD, Andrés Farall, PhD, Gabriela Lamas, MD, Fabiana Lubieniecki, MD, David H. Abramson, MD, Paula Schaiquevich, PhD   +8 more
doaj   +2 more sources

Suprachoroidal Injection of Topotecan for Retinoblastoma: A Preclinical Study [PDF]

Ophthalmology Science
Purpose: To assess whether levels of topotecan that are expected to be therapeutic against retinoblastoma tumors can be achieved within the retina and choroid by suprachoroidal injection (SCI) and to assess toxicity and safety in vivo.
Arun D. Singh, MD, Vishal Raval, MD, Sandeep Kumar, PhD, Anthony Daniels, MD   +3 more
doaj   +2 more sources

Real-Time Positron Emission Tomography Evaluation of Topotecan Brain Kinetics after Ultrasound-Mediated Blood–Brain Barrier Permeability

Pharmaceutics, 2021
Glioblastoma (GBM) is the most common primary adult brain malignancy with an extremely poor prognosis and a median survival of fewer than two years.
Andrei Molotkov, Patrick Carberry, Martin A. Dolan, Simon Joseph, Sidney Idumonyi, Shunichi Oya, John Castrillon, Elisa E. Konofagou, Mikhail Doubrovin, Glenn J. Lesser, Francesca Zanderigo, Akiva Mintz   +11 more
doaj   +1 more source

Elucidation of Mechanisms of Topotecan-Induced Cell Death in Human Breast MCF-7 Cancer Cells by Gene Expression Analysis

Frontiers in Genetics, 2020
Topotecan is a clinically active anticancer agent for the management of various human tumors. While the principal mechanism of tumor cell killing by topotecan is due to its interactions with topoisomerase I and formation of DNA double-strand breaks ...
Birandra K. Sinha, Erik J. Tokar, Pierre R. Bushel   +2 more
doaj   +1 more source

Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer

Drug Delivery, 2021
Topotecan is potent anti-cancer drug approved for various malignancies but hematopoietic toxicities undermine its wider application and use of its most effective dose. This study aims to improve these limitations through inhalation-delivery.
Philip J. Kuehl, Christin M. Yingling, Devon Dubose, Michael Burke, David A. Revelli, Wenshu Chen, Wendy W. Dye, Steven A. Belinsky, Mathewos Tessema   +8 more
doaj   +1 more source

DNA repair and cholesterol-mediated drug efflux induce dose-dependent chemoresistance in nutrient-deprived neuroblastoma cells

iScience, 2021
Summary: Neuroblastoma is a solid, heterogeneous pediatric tumor. Chemotherapy is widely used to treat neuroblastoma. However, dose-dependent responses and chemoresistance mechanisms of neuroblastoma cells to anticancer drugs remain challenging. Here, we
Soo Yeon Chae, Dowoon Nam, Do Young Hyeon, Areum Hong, Timothy Dain Lee, Sujin Kim, Dongjoon Im, Jiwon Hong, Chaewon Kang, Ji Won Lee, Daehee Hwang, Sang-Won Lee, Hugh I. Kim   +12 more
doaj   +1 more source

The Lipophilic Purine Nucleoside—Tdp1 Inhibitor—Enhances DNA Damage Induced by Topotecan In Vitro and Potentiates the Antitumor Effect of Topotecan In Vivo

Molecules, 2022
The use of cancer chemotherapy sensitizers is a promising approach to induce the effect of clinically used anticancer treatments. One of the interesting targets is Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), a DNA-repair enzyme, that may prevent the action ...
Irina A. Chernyshova, Aleksandra L. Zakharenko, Nikolay N. Kurochkin, Nadezhda S. Dyrkheeva, Tatyana E. Kornienko, Nelly A. Popova, Valeriy P. Nikolin, Ekaterina S. Ilina, Timofey D. Zharkov, Maxim S. Kupryushkin, Vladimir E. Oslovsky, Mikhail S. Drenichev, Olga I. Lavrik   +12 more
doaj   +1 more source

The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation

Health Technology Assessment, 2010
Objectives: To assess the clinical effectiveness and cost-effectiveness of topotecan as second-line treatment for small cell lung cancer (SCLC). Data sources: Bibliographic databases were searched from 1990 to February 2009, including the Cochrane ...
E Loveman, J Jones, D Hartwell, A Bird, P Harris, K Welch, A Clegg   +6 more
doaj   +1 more source